Atul Ltd 2014-15

Atul Ltd | Annual Report 2014-15 Pharmaceuticals Product Groups: Active Pharmaceutical Ingredients, API Intermediates, Others The products falling under these product groups are used by customers belonging to Pharmaceutical industry for various therapeutic categories, such as anti-depressant, anti-diabetic, anti-infective, anti-retroviral and cardiovascular. The product groups comprise about 50 products. Cbz- L-Valine, 1-Chloroethyl isopropyl carbonate and (S)-1-(2-chloroacetyl) pyrrolidine-2-carbonitrile are some of the key products. During 2014-15, sales increased by 9% from ` 306 cr to ` 334 cr. Sales in India increased by 8% from ` 172 cr to ` 186 cr. Sales outside India increased by 10% from ` 134 cr to ` 148 cr and formed 44% of the total. Growth on account of volume was 9%. The Company received its first USFDA approval for one of its products; it is in the process of expanding its API plant. Atul Bioscience Ltd (ABL), a 100% subsidiary company, focussed on production of advanced API intermediates and increased its sales by 37% from ` 35 cr to ` 47 cr, primarily because of volume; it undertook 1 project for implementation. The size of world API industry is estimated at US$ 120 b and is growing at about 9.4%. There are about 20 major companies which dominate the world marketplace. The size of world Pharmaceutical industry is estimated at US$ 0.8 t and is growing at about 8%. The main user industry, namely, Pharmaceutical, is growing well because of increasing awareness about diseases and health. The Company along with ABL will participate in this growth by i) widening its market reach, ii) increasing its manufacturing efficiencies, iii) generating and adding capacities and iv) introducing new products. It will also form long-term strategic alliances with other companies. The prices of some products may come down in a short time. Fluctuations in foreign exchange may impact sales realisations.